About Us
Katya Tsaioun, Ph.D.
Bruno Villoutreix, Ph.D.
Bruno Villoutreix, Ph.D.
20+ years experience in academia and Boston area biotech industry; successful entrepreneur (founded Apredica, an ADME-Tox CRO in 2006, exit to Cyprotex, PLC (now Evotec)); expertise in ADME-Tox and mechanistic strategies for hit-to-lead, lead optimization and de-risking drug-discovery programs.
Bruno Villoutreix, Ph.D.
Bruno Villoutreix, Ph.D.
Bruno Villoutreix, Ph.D.
25+ years international experience at the interface between molecular medicine (cancer, complement system, blood coagulation), structural bioinformatics and chemoinformatics both in the private and academic sectors in USA, Finland, Sweden, Bulgaria, France. Research director at INSERM U1141, Hospital Robert Debré, Paris, France. Biomolecular modeling, drug design, ADME-Tox prediction.
Lana Gladstein, J.D.
Bruno Villoutreix, Ph.D.
Usamah Kayyali, Ph.D.
Chief Legal Officer, Arranta Bio; previously EVP and General Counsel of Brammer Bio (exit to Thermo Fisher in 2019); formerly partner at Troutman Pepper, and partner at Nutter, Boston, MA
Usamah Kayyali, Ph.D.
Usamah Kayyali, Ph.D.
Usamah Kayyali, Ph.D.
Dr. Usamah Kayyali previously conducted research over two decades in molecular and cell biology of disease at Harvard and Tufts Universities, which was funded by the NIH and other agencies. His lab demonstrated a role for p38 MAP kinase-MK2 activation in augmenting the vascular endothelium, and developed an MK2-activating peptide as a p
Dr. Usamah Kayyali previously conducted research over two decades in molecular and cell biology of disease at Harvard and Tufts Universities, which was funded by the NIH and other agencies. His lab demonstrated a role for p38 MAP kinase-MK2 activation in augmenting the vascular endothelium, and developed an MK2-activating peptide as a potential drug. He currently serves as Scientific Advisor for Akttyva.
Mark Tepper, Ph.D.
Usamah Kayyali, Ph.D.
Mario DiPaola, Ph.D.
Dr. Tepper has over 30 years of experience in the biotechnology and pharmaceutical industry. He has led drug discovery & development programs that span a wide range of therapeutic areas including Oncology, Immunology, Rheumatology, Endocrinology, Metabolic Diseases, CNS Diseases, Inflammation and Pain. In addition, he has founded multip
Dr. Tepper has over 30 years of experience in the biotechnology and pharmaceutical industry. He has led drug discovery & development programs that span a wide range of therapeutic areas including Oncology, Immunology, Rheumatology, Endocrinology, Metabolic Diseases, CNS Diseases, Inflammation and Pain. In addition, he has founded multiple companies based on novel technologies in the area of RNA interference, structure-based drug design, small molecule and protein therapeutics, biosensors, microfluidics and biomaterials. He has taken 2 of his companies public (RXii & CRBP) and sold one in a trade sale to KNSA.
Mario DiPaola, Ph.D.
Usamah Kayyali, Ph.D.
Mario DiPaola, Ph.D.
Dr. Mario DiPaola is an experienced executive with a 25-year record in the biotechnology and pharmaceutical industries. He is the founder or co-founder of a number of companies, including Blue Stream Labs Inc., Oncovolution LLC, Therabene LLC and Higher-Order Technologies LLC. He is also the author of several patents and 50+ publications.